EF
NBIX icon

Empowered Funds’s Neurocrine Biosciences NBIX Stock Holding History

Empowered Funds’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,386
Closed -$1.6M – 646
2022
Q4 		$1.6M Buy
+13,386
New +$1.57M 0.1% 204

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Empowered Funds's NBIX Position: Q1 2026 in Review

Empowered Funds increased its Neurocrine Biosciences (NBIX) stake by 1,823% in Q1 2026, buying an estimated $10.6M and bringing the position to 83,971 shares worth $11.1M. The position accounts for 0.07% of the portfolio, ranked #344.

Empowered Funds first reported a position in NBIX in Q1 2023 and has held it in 12 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Empowered Funds held 83,971 shares of Neurocrine Biosciences worth $11.1M as of Q1 2026.
  • Empowered Funds bought 79,605 Neurocrine Biosciences shares in Q1 2026, an estimated $10.6M.
  • Neurocrine Biosciences made up 0.07% of Empowered Funds's portfolio in Q1 2026, its #344 holding.
  • Empowered Funds first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 12 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.